San Francisco startup Framework Therapeutics is also working on an oral, after-day-to-day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s expectations in June every time a mid-phase research showed regular weight loss of all around 6% and it strategies to begin One more mid-stage trial toward the tip of this yr—that founder and